KR102215792B1 - 키나제 억제제로서 유용한 화합물 - Google Patents

키나제 억제제로서 유용한 화합물 Download PDF

Info

Publication number
KR102215792B1
KR102215792B1 KR1020187020225A KR20187020225A KR102215792B1 KR 102215792 B1 KR102215792 B1 KR 102215792B1 KR 1020187020225 A KR1020187020225 A KR 1020187020225A KR 20187020225 A KR20187020225 A KR 20187020225A KR 102215792 B1 KR102215792 B1 KR 102215792B1
Authority
KR
South Korea
Prior art keywords
mmol
substituted
alkyl
methyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187020225A
Other languages
English (en)
Korean (ko)
Other versions
KR20180115261A (ko
Inventor
니콜라스 귀소
Original Assignee
록쏘 온콜로지, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1522245.8A external-priority patent/GB201522245D0/en
Priority claimed from GBGB1613945.3A external-priority patent/GB201613945D0/en
Application filed by 록쏘 온콜로지, 인코포레이티드 filed Critical 록쏘 온콜로지, 인코포레이티드
Publication of KR20180115261A publication Critical patent/KR20180115261A/ko
Application granted granted Critical
Publication of KR102215792B1 publication Critical patent/KR102215792B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020187020225A 2015-12-16 2016-12-16 키나제 억제제로서 유용한 화합물 Active KR102215792B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1522245.8 2015-12-16
GBGB1522245.8A GB201522245D0 (en) 2015-12-16 2015-12-16 Compounds useful as kinase inhibitors
GB1613945.3 2016-08-15
GBGB1613945.3A GB201613945D0 (en) 2016-08-15 2016-08-15 Compounds useful as kinase inhibitors
PCT/GB2016/053968 WO2017103611A1 (en) 2015-12-16 2016-12-16 Compounds useful as kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217003683A Division KR20210018530A (ko) 2015-12-16 2016-12-16 키나제 억제제로서 유용한 화합물

Publications (2)

Publication Number Publication Date
KR20180115261A KR20180115261A (ko) 2018-10-22
KR102215792B1 true KR102215792B1 (ko) 2021-02-16

Family

ID=57590725

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187020225A Active KR102215792B1 (ko) 2015-12-16 2016-12-16 키나제 억제제로서 유용한 화합물
KR1020217003683A Withdrawn KR20210018530A (ko) 2015-12-16 2016-12-16 키나제 억제제로서 유용한 화합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217003683A Withdrawn KR20210018530A (ko) 2015-12-16 2016-12-16 키나제 억제제로서 유용한 화합물

Country Status (37)

Country Link
US (8) US10695323B2 (enExample)
EP (2) EP3782994B1 (enExample)
JP (3) JP6731483B2 (enExample)
KR (2) KR102215792B1 (enExample)
CN (9) CN113603645B (enExample)
AU (4) AU2016373530B2 (enExample)
CA (1) CA3008488C (enExample)
CL (1) CL2018001591A1 (enExample)
CO (1) CO2018006164A2 (enExample)
CR (1) CR20180367A (enExample)
CY (2) CY1123561T1 (enExample)
DK (1) DK3390395T3 (enExample)
EA (1) EA035132B1 (enExample)
ES (2) ES2828431T3 (enExample)
FI (1) FIC20240004I1 (enExample)
FR (1) FR24C1009I2 (enExample)
HR (1) HRP20201835T1 (enExample)
HU (2) HUE051921T2 (enExample)
IL (4) IL285976B2 (enExample)
LT (2) LT3390395T (enExample)
MA (2) MA55064A (enExample)
MD (1) MD3390395T2 (enExample)
MX (2) MX394193B (enExample)
MY (2) MY202026A (enExample)
NL (1) NL301262I2 (enExample)
NO (1) NO2024008I1 (enExample)
NZ (1) NZ743553A (enExample)
PE (3) PE20220507A1 (enExample)
PH (1) PH12018501268A1 (enExample)
PT (1) PT3390395T (enExample)
RS (1) RS60982B9 (enExample)
SG (2) SG11201805044WA (enExample)
SI (1) SI3390395T1 (enExample)
TN (1) TN2018000213A1 (enExample)
UA (2) UA127863C2 (enExample)
WO (1) WO2017103611A1 (enExample)
ZA (4) ZA201804137B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
HK1258779A1 (zh) 2015-09-16 2019-11-22 Loxo Oncology Inc. 用於治療癌症的作為btk抑制劑的吡唑並嘧啶衍生物
MA55064A (fr) * 2015-12-16 2021-09-29 Loxo Oncology Inc Composés utilisés comme inhibiteurs de kinase
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
US10829485B2 (en) * 2018-04-06 2020-11-10 Black Belt Tx Ltd ATF6 inhibitors and uses thereof
CN112119063B (zh) * 2018-05-18 2023-10-17 富士胶片株式会社 3-二氟甲基吡唑化合物的制造方法及3-二氟甲基吡唑-4-羧酸化合物的制造方法以及吡唑烷化合物
KR102653681B1 (ko) * 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
WO2021053234A1 (en) * 2019-09-19 2021-03-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Compounds and compositions for treating kidney disease
CN110724135B (zh) * 2019-11-18 2023-04-28 上海医药工业研究院有限公司 一种艾拉普林中间体及其制备方法
KR20220100992A (ko) * 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여
EP4087845A4 (en) 2020-01-02 2024-01-24 Dizal (Jiangsu) Pharmaceutical Co., Ltd. BTK INHIBITORS
CN115443277A (zh) * 2020-03-12 2022-12-06 重庆复尚源创医药技术有限公司 作为激酶抑制剂的化合物
TW202317099A (zh) * 2020-09-10 2023-05-01 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
CN112386597B (zh) * 2020-10-15 2022-03-15 天津济坤医药科技有限公司 泽布替尼在制备治疗肺纤维化疾病药物中的应用
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022228302A1 (en) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Heteroaromatic carboxamide compounds and its use
MX2023013443A (es) * 2021-05-14 2023-12-12 Loxo Oncology Inc Formas cocristalinas de un inhibidor de la tirosina cinasa de bruton.
JP2024524480A (ja) * 2021-07-01 2024-07-05 ハンチョウ、ヘルズン、セラピューティクス、カンパニー、リミテッド ブルトン型チロシンキナーゼ及びその突然変異体の分解剤、組成物並びにそれらの応用
WO2023284765A1 (zh) * 2021-07-16 2023-01-19 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
WO2023110970A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Macrocyclic btk inhibitors
WO2023143355A1 (en) * 2022-01-28 2023-08-03 Hansoh Bio Llc Azacycle amide derivative, preparation methods and medicinal uses thereof
EP4474377A4 (en) * 2022-03-03 2025-07-30 Shenzhen Targetrx Inc Cycloalkyl or heterocyclyl substituted heteroaryl compound, and composition and use thereof
CN119053592A (zh) * 2022-03-18 2024-11-29 英矽智能科技知识产权有限公司 吡唑膜相关的酪氨酸和苏氨酸特异性cdc2抑制激酶(pkmyt1)抑制剂及其用途
CN115894376B (zh) * 2022-12-15 2025-05-16 南京雷正医药科技有限公司 一种芳香族酰胺类化合物、药物组合物及其用途
WO2024176164A1 (en) 2023-02-22 2024-08-29 Assia Chemical Industries Ltd. Solid state form of pirtobrutinib
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
KR20250046558A (ko) 2023-09-27 2025-04-03 임창섭 5g 사물인터넷 기반 하드월렛 간의 디지털자산 안심이체 시스템
TW202532067A (zh) * 2023-12-13 2025-08-16 大陸商正大天晴藥業集團股份有限公司 含有吡唑環及雙環雜芳基的化合物
WO2025137329A1 (en) * 2023-12-22 2025-06-26 Neupharma, Inc Certain chemical entities, compositions, and methods
CN119059973A (zh) * 2024-08-12 2024-12-03 武汉九州钰民医药科技有限公司 一种吡托布鲁替尼的合成工艺
CN119059974B (zh) * 2024-08-12 2025-10-28 武汉九州钰民医药科技有限公司 一种吡托布鲁替尼的制备方法
CN120504661B (zh) * 2025-07-14 2025-11-07 复旦大学 Alkbh8小分子抑制剂及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110144068A1 (en) 2008-07-24 2011-06-16 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
WO2014068527A1 (en) 2012-11-02 2014-05-08 Pfizer Inc. Bruton's tyrosine kinase inhibitors
WO2014082598A1 (en) 2012-11-30 2014-06-05 Centaurus Biopharma Co., Ltd. Inhibitors of bruton's tyrosine kinase
WO2015140566A1 (en) 2014-03-20 2015-09-24 Redx Pharma Plc Pyrazolo-pyrimidines as inhibitors of btk
KR101813931B1 (ko) 2010-06-30 2018-01-02 아이언우드 파마슈티컬스, 인코포레이티드 Sgc 자극제

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60004685T2 (de) 1999-09-17 2004-07-29 Abbott Gmbh & Co. Kg Pyrazolopyrimidine als arzneimittel
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6291504B1 (en) * 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
PT2201840E (pt) 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
WO2008063287A2 (en) * 2006-10-06 2008-05-29 Abbott Laboratories Novel imidazothiazoles and imidazoxazoles
EP2089391B1 (en) 2006-11-03 2013-01-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
EA017865B1 (ru) 2007-03-28 2013-03-29 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
TWI458721B (zh) 2008-06-27 2014-11-01 Celgene Avilomics Res Inc 雜芳基化合物及其用途
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2009270856B2 (en) 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
EA201890869A3 (ru) 2010-06-03 2019-03-29 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk)
PL2710005T3 (pl) 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
ES2770550T3 (es) 2011-05-17 2020-07-02 Univ California Inhibidores de quinasa
AU2012283775A1 (en) 2011-07-13 2014-01-23 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
AU2013277582B2 (en) 2012-06-18 2017-11-30 Principia Biopharma Inc. Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
US9572811B2 (en) 2012-08-03 2017-02-21 Principia Biopharma Inc. Treatment of dry eye
IN2015DN00524A (enExample) * 2012-08-10 2015-06-26 Boehringer Ingelheim Int
GB201214750D0 (en) * 2012-08-17 2012-10-03 Respivert Ltd Compounds
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
GB201309085D0 (en) 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
SG11201602070TA (en) * 2013-09-30 2016-04-28 Beijing Synercare Pharma Tech Co Ltd Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
WO2015075051A1 (en) * 2013-11-19 2015-05-28 Universitaet Des Saarlandes Allosteric inhibitors of atypical protein kinases c
US9637486B2 (en) 2013-12-20 2017-05-02 Merck Sharp & Dohme Corp. Btk inhibitors
KR20220027271A (ko) 2014-02-21 2022-03-07 프린시피아 바이오파마, 인코퍼레이티드 Btk 억제제의 염 및 고체 형태
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
CR20170345A (es) 2015-01-28 2017-09-29 Bayer Pharma Aktiengesellchaft Derivados de 4h-pirrol[3,2-c]piridin-4-ona
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
HK1258779A1 (zh) 2015-09-16 2019-11-22 Loxo Oncology Inc. 用於治療癌症的作為btk抑制劑的吡唑並嘧啶衍生物
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
NZ742709A (en) 2015-12-16 2019-09-27 Ecolab Usa Inc Peroxyformic acid compositions for membrane filtration cleaning
JP6856662B2 (ja) 2015-12-16 2021-04-07 プライオスター プロプライアタリー リミティド デンドリマー及びその製剤
US9975882B2 (en) 2015-12-16 2018-05-22 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
SG11201804674UA (en) 2015-12-16 2018-06-28 Bristol Myers Squibb Co Heteroarylhydroxypyrimidinones as agonists of the apj receptor
MA55064A (fr) 2015-12-16 2021-09-29 Loxo Oncology Inc Composés utilisés comme inhibiteurs de kinase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110144068A1 (en) 2008-07-24 2011-06-16 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
KR101813931B1 (ko) 2010-06-30 2018-01-02 아이언우드 파마슈티컬스, 인코포레이티드 Sgc 자극제
WO2014068527A1 (en) 2012-11-02 2014-05-08 Pfizer Inc. Bruton's tyrosine kinase inhibitors
WO2014082598A1 (en) 2012-11-30 2014-06-05 Centaurus Biopharma Co., Ltd. Inhibitors of bruton's tyrosine kinase
WO2015140566A1 (en) 2014-03-20 2015-09-24 Redx Pharma Plc Pyrazolo-pyrimidines as inhibitors of btk

Also Published As

Publication number Publication date
CN114573510B (zh) 2025-02-25
CN114716381A (zh) 2022-07-08
MX394193B (es) 2025-03-21
JP2018538307A (ja) 2018-12-27
AU2021225162A1 (en) 2021-09-30
CL2018001591A1 (es) 2018-09-28
US20210093611A1 (en) 2021-04-01
ZA202107471B (en) 2023-03-29
US20250090500A1 (en) 2025-03-20
US10464905B2 (en) 2019-11-05
MA55064A (fr) 2021-09-29
SG11201805044WA (en) 2018-07-30
US11471441B2 (en) 2022-10-18
NZ743553A (en) 2022-08-26
CN113603645A (zh) 2021-11-05
IL285976B2 (en) 2023-10-01
UA122258C2 (uk) 2020-10-12
PE20220502A1 (es) 2022-04-07
US12220401B2 (en) 2025-02-11
JP6731483B2 (ja) 2020-07-29
AU2016373530B2 (en) 2021-01-21
PH12018501268A1 (en) 2019-02-18
HUE051921T2 (hu) 2021-03-29
US10342780B2 (en) 2019-07-09
EP3782994B1 (en) 2025-07-16
IL259923B (en) 2020-08-31
PE20220507A1 (es) 2022-04-07
FR24C1009I2 (fr) 2025-02-07
FR24C1009I1 (fr) 2024-05-24
JP2022120013A (ja) 2022-08-17
FIC20240004I1 (fi) 2024-03-01
DK3390395T3 (da) 2020-09-28
CY2024003I2 (el) 2024-09-20
LT3390395T (lt) 2020-11-25
US20180362512A1 (en) 2018-12-20
MD3390395T2 (ro) 2021-02-28
CN108473481A (zh) 2018-08-31
CN113603645B (zh) 2024-10-29
JP7419437B2 (ja) 2024-01-22
NO2024008I1 (no) 2024-02-29
AU2021225161A1 (en) 2021-09-30
ES2828431T3 (es) 2021-05-26
IL285976A (en) 2021-10-31
HK1263254A1 (en) 2020-02-21
MX380907B (es) 2025-03-12
US20220062239A1 (en) 2022-03-03
CN113636978B (zh) 2024-10-29
RS60982B1 (sr) 2020-11-30
CN114634447B (zh) 2024-11-15
ZA202107472B (en) 2023-03-29
CN114621146A (zh) 2022-06-14
CA3008488C (en) 2023-10-10
JP7086140B2 (ja) 2022-06-17
CN114605327B (zh) 2025-03-11
MX2021003478A (es) 2022-07-25
IL281067A (en) 2021-04-29
US20190000806A1 (en) 2019-01-03
EP3390395A1 (en) 2018-10-24
CN108473481B (zh) 2022-04-19
CN114573510A (zh) 2022-06-03
RS60982B9 (sr) 2025-07-31
CA3008488A1 (en) 2017-06-22
MX2018007267A (es) 2018-11-09
KR20210018530A (ko) 2021-02-17
MA49809A1 (fr) 2021-08-31
JP2020172535A (ja) 2020-10-22
CN114716381B (zh) 2025-03-11
HUS2400003I1 (hu) 2024-03-28
KR20180115261A (ko) 2018-10-22
CR20180367A (es) 2018-11-12
EP3390395B1 (en) 2020-09-09
UA127863C2 (uk) 2024-01-31
CN114634447A (zh) 2022-06-17
US10918622B2 (en) 2021-02-16
EP3782994A1 (en) 2021-02-24
EA035132B1 (ru) 2020-04-30
PE20181449A1 (es) 2018-09-12
BR112018012341A2 (pt) 2018-12-04
AU2016373530A1 (en) 2018-07-05
SG10202012498TA (en) 2021-01-28
HRP20201835T1 (hr) 2021-01-08
IL285976B1 (en) 2023-06-01
US11826351B2 (en) 2023-11-28
IL281067B (en) 2022-04-01
CO2018006164A2 (es) 2018-09-20
AU2021225161B2 (en) 2023-08-03
US20230372298A1 (en) 2023-11-23
EA201891268A1 (ru) 2018-11-30
LTPA2024506I1 (enExample) 2024-03-25
SI3390395T1 (sl) 2020-11-30
NL301262I2 (nl) 2024-04-24
CN114591242A (zh) 2022-06-07
CN113636978A (zh) 2021-11-12
US20200276162A1 (en) 2020-09-03
IL276283A (en) 2020-09-30
ES3041897T3 (en) 2025-11-17
MY202026A (en) 2024-03-29
TN2018000213A1 (en) 2019-10-04
AU2021201811B2 (en) 2022-01-27
AU2021201811A1 (en) 2021-04-22
US20190135762A1 (en) 2019-05-09
PT3390395T (pt) 2020-11-03
US10695323B2 (en) 2020-06-30
CN114605327A (zh) 2022-06-10
ZA202100544B (en) 2023-06-28
CY1123561T1 (el) 2022-03-24
CN114591242B (zh) 2025-01-07
IL259923A (en) 2018-07-31
MY200590A (en) 2024-01-04
WO2017103611A1 (en) 2017-06-22
ZA201804137B (en) 2022-08-31
IL276283B (en) 2021-03-25
AU2021225162B2 (en) 2023-08-03
CY2024003I1 (el) 2024-09-20

Similar Documents

Publication Publication Date Title
US12220401B2 (en) Compounds useful as kinase inhibitors
HK40059756A (en) Compounds useful as kinase inhibitors
HK40059212A (en) Compounds useful as kinase inhibitors
BR112018012341B1 (pt) Compostos inibidores de quinase, seus usos, e composição farmacêutica

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180713

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200206

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20200507

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200902

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20201109

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210205

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210208

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210209

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240130

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20250210

Start annual number: 5

End annual number: 5